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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
In their Comment (April issue),1 
Kishwar Azad and Anthony Costello 
raise questions that should be answered 
before antenatal corticosteroid treat-
ment is scaled up to reduce pre term 
deaths in low-income countries. We 
share their concerns about the unknown 
overall effect of this treatment on 
mortality and potential safety issues in 
the mother. To answer these questions, 
we have initiated the Antenatal 
Corticosteroids Trial2 to assess whether 
or not a multifaceted intervention 
to increase the use of antenatal 
corticosteroids reduces neonatal 
mortality at 28 days of age, and 
maternal morbidity due to infections. 
Enrolment has been completed and 
data from more than 90 000 births have 
been collected.
We disagree with Azad and Costello’s 
comment about the eﬀ ect of antenatal 
corticosteroid treatment on respiratory 
distress in infants at 34 weeks’ 
gestation. This statement is based on 
a subgroup analysis from a systematic 
review.3 However, the same review 
presents data showing a decreased 
risk of respiratory distress syndrome 
in infants with first dose of cortico-
steroids administered to mothers 
at 33–35 weeks’ gestation (relative 
risk [RR] 0·53, 95% CI 0·31–0·91), 
and a non-signiﬁ cant decrease in the 
risk of respiratory distress in infants 
(0·61, 0·11–3·26) with first dose at 
35–37 weeks’ gestation. The ﬁ ndings 
suggest a reduction in respiratory 
distress syndrome is present according 
to gestational age at ﬁ rst delivery of 
corticosteroids.3 
Prevention of respiratory distress 
syndrome in infants born at 
33–36 weeks’ gestation without access 
to specialised high-quality level 2 care 
might create a substantial health-care 
burden in low-income countries. The 
Antenatal Corticosteroids Trial2 will 
assess the administration of steroids 
to mothers up to 36 weeks’ gestation. 
Data from this trial will be available in 
the second half of 2014. We hope that 
several of the concerns expressed in 
the Comment by Azad and Costello 
will be addressed. 
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